Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBIO BridgeBio Pharma	$38.62 +0.7%	$34.44	$21.62 ▼ $39.66	$7.33B	1.15	2.47 million shs	2.68 million shs
ELAN Elanco Animal Health	$13.95 +3.8%	$10.90	$8.02 ▼ $18.80	$6.93B	1.49	5.14 million shs	7.02 million shs
TARS Tarsus Pharmaceuticals	$43.92 -0.4%	$46.32	$20.08 ▼ $57.28	$1.85B	0.83	702,986 shs	625,505 shs
VRNA Verona Pharma	$84.34 -1.4%	$67.26	$11.79 ▼ $86.59	$6.84B	0.2	1.32 million shs	1.74 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBIO BridgeBio Pharma	+0.84%	+14.89%	+3.79%	+21.44%	+36.93%
ELAN Elanco Animal Health	-0.19%	-0.63%	+40.98%	+20.83%	-27.18%
TARS Tarsus Pharmaceuticals	+3.40%	+1.52%	-5.06%	-5.10%	+31.17%
VRNA Verona Pharma	+1.86%	+10.39%	+22.08%	+32.31%	+604.61%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BBIO BridgeBio Pharma	4.4182 of 5 stars	4.5	1.0	3.9	2.0	3.3	0.6
ELAN Elanco Animal Health	1.3758 of 5 stars	1.2	1.0	0.3	2.5	3.3	0.0
TARS Tarsus Pharmaceuticals	2.772 of 5 stars	3.5	2.0	0.0	3.3	2.5	0.6
VRNA Verona Pharma	1.6403 of 5 stars	2.6	1.0	0.0	3.1	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BBIO BridgeBio Pharma	2.92	Moderate Buy	$57.09	47.83% Upside
ELAN Elanco Animal Health	2.43	Hold	$15.17	8.76% Upside
TARS Tarsus Pharmaceuticals	3.00	Buy	$66.67	51.79% Upside
VRNA Verona Pharma	3.11	Buy	$82.13	-2.63% Downside

Current Analyst Ratings Breakdown

Latest TARS, VRNA, BBIO, and ELAN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/2/2025	TARS Tarsus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$75.00
6/2/2025	VRNA Verona Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$85.00 ➝ $90.00
5/27/2025	TARS Tarsus Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$72.00
5/19/2025	ELAN Elanco Animal Health	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $16.00
5/8/2025	ELAN Elanco Animal Health	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$13.00 ➝ $15.00
5/5/2025	TARS Tarsus Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$46.00 ➝ $51.00
5/2/2025	TARS Tarsus Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$78.00 ➝ $84.00
4/30/2025	BBIO BridgeBio Pharma	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$46.00 ➝ $63.00
4/30/2025	BBIO BridgeBio Pharma	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$52.00 ➝ $55.00
4/30/2025	BBIO BridgeBio Pharma	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$65.00 ➝ $72.00
4/30/2025	VRNA Verona Pharma	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$93.00 ➝ $107.00

(Data available from 6/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BBIO BridgeBio Pharma	$127.42M	57.55	N/A	N/A	($7.71) per share	-5.01
ELAN Elanco Animal Health	$4.43B	1.56	$2.88 per share	4.84	$12.63 per share	1.10
TARS Tarsus Pharmaceuticals	$233.67M	7.90	N/A	N/A	$5.95 per share	7.38
VRNA Verona Pharma	$118.54M	57.69	N/A	N/A	$3.10 per share	27.21

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BBIO BridgeBio Pharma	-$535.76M	-$3.53	N/A	N/A	N/A	-241.44%	N/A	-75.69%	7/30/2025 (Estimated)
ELAN Elanco Animal Health	-$1.23B	$0.74	34.86	15.67	2.50	4.60%	6.78%	3.03%	8/14/2025 (Estimated)
TARS Tarsus Pharmaceuticals	-$135.89M	-$2.73	N/A	N/A	N/A	-103.64%	-55.86%	-39.28%	8/6/2025 (Estimated)
VRNA Verona Pharma	-$54.37M	-$2.00	N/A	2,811.33	N/A	N/A	-79.54%	-43.49%	8/14/2025 (Estimated)

Latest TARS, VRNA, BBIO, and ELAN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/7/2025	Q1 2025	ELAN Elanco Animal Health	$0.31	$0.37	+$0.06	$0.14	$1.17 billion	$1.19 billion
5/1/2025	Q1 2025	TARS Tarsus Pharmaceuticals	-$0.69	-$0.64	+$0.05	-$0.64	$72.50 million	$78.34 million
4/29/2025	Q1 2025	BBIO BridgeBio Pharma	-$1.00	-$0.88	+$0.12	-$0.88	$57.14 million	$36.74 million
4/29/2025	Q1 2025	VRNA Verona Pharma	-$0.22	$0.27	+$0.49	-$0.16	$41.47 million	$98.65 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BBIO BridgeBio Pharma	N/A	N/A	N/A	N/A	N/A
ELAN Elanco Animal Health	N/A	N/A	N/A	N/A	N/A
TARS Tarsus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VRNA Verona Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BBIO BridgeBio Pharma	N/A	4.67	4.67
ELAN Elanco Animal Health	0.66	2.55	1.31
TARS Tarsus Pharmaceuticals	0.30	5.42	5.38
VRNA Verona Pharma	0.93	13.03	12.88

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BBIO BridgeBio Pharma	99.85%
ELAN Elanco Animal Health	97.48%
TARS Tarsus Pharmaceuticals	90.01%
VRNA Verona Pharma	85.88%

Insider Ownership

Company	Insider Ownership
BBIO BridgeBio Pharma	18.20%
ELAN Elanco Animal Health	0.89%
TARS Tarsus Pharmaceuticals	8.97%
VRNA Verona Pharma	4.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BBIO BridgeBio Pharma	400	189.88 million	143.29 million	Optionable
ELAN Elanco Animal Health	9,800	496.65 million	491.54 million	Optionable
TARS Tarsus Pharmaceuticals	50	42.01 million	35.07 million	Optionable
VRNA Verona Pharma	30	81.08 million	76.10 million	Optionable

TARS, VRNA, BBIO, and ELAN Headlines

Recent News About These Companies

RFG Advisory LLC Invests $1.48 Million in Verona Pharma plc (NASDAQ:VRNA)

June 5 at 5:11 AM | marketbeat.com

Hennion & Walsh Asset Management Inc. Purchases 5,766 Shares of Verona Pharma plc (NASDAQ:VRNA)

June 3 at 7:46 AM | marketbeat.com

Hamilton Lane Advisors LLC Takes $1.65 Million Position in Verona Pharma plc (NASDAQ:VRNA)

June 3 at 6:44 AM | marketbeat.com

HC Wainwright Forecasts Strong Price Appreciation for Verona Pharma (NASDAQ:VRNA) Stock

June 3 at 2:09 AM | americanbankingnews.com

Verona Pharma (NASDAQ:VRNA) Reaches New 12-Month High Following Analyst Upgrade

June 3 at 1:15 AM | americanbankingnews.com

Verona Pharma (NASDAQ:VRNA) Hits New 1-Year High After Analyst Upgrade

June 2, 2025 | marketbeat.com

Verona Pharma (NASDAQ:VRNA) Price Target Raised to $90.00 at HC Wainwright

June 2, 2025 | marketbeat.com

Two Sigma Advisers LP Buys New Shares in Verona Pharma plc (NASDAQ:VRNA)

June 2, 2025 | marketbeat.com

7,800 Shares in Verona Pharma plc (NASDAQ:VRNA) Acquired by Northern Trust Corp

June 2, 2025 | marketbeat.com

Verona Pharma plc (NASDAQ:VRNA) Shares Sold by Bank of America Corp DE

June 1, 2025 | marketbeat.com

Verona Pharma (NASDAQ:VRNA) Shares Gap Up - What's Next?

June 1, 2025 | americanbankingnews.com

Verona Pharma plc (NASDAQ:VRNA) CFO Mark W. Hahn Sells 32,432 Shares

May 31, 2025 | marketbeat.com

Verona Pharma plc (NASDAQ:VRNA) CEO Sells $320,208.00 in Stock

May 31, 2025 | marketbeat.com

David Zaccardelli Sells 157,704 Shares of Verona Pharma plc (NASDAQ:VRNA) Stock

May 31, 2025 | marketbeat.com

Verona Pharma plc (NASDAQ:VRNA) CFO Mark W. Hahn Sells 162,704 Shares

May 31, 2025 | marketbeat.com

Verona Pharma plc (NASDAQ:VRNA) CFO Mark W. Hahn Sells 204,864 Shares

May 31, 2025 | marketbeat.com

David Zaccardelli Sells 208,696 Shares of Verona Pharma plc (NASDAQ:VRNA) Stock

May 31, 2025 | marketbeat.com

Verona Pharma (NASDAQ:VRNA) Shares Gap Up - Time to Buy?

May 31, 2025 | marketbeat.com

10,310 Shares in Verona Pharma plc (NASDAQ:VRNA) Bought by NorthCrest Asset Manangement LLC

May 31, 2025 | marketbeat.com

Verona Pharma plc (NASDAQ:VRNA) CFO Sells $309,076.96 in Stock

May 30, 2025 | insidertrades.com

Jim Cramer Notes Verona Pharma plc (VRNA) “Loses a Lot of Money”

May 29, 2025 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TARS, VRNA, BBIO, and ELAN Company Descriptions

BridgeBio Pharma NASDAQ:BBIO

$38.62 +0.28 (+0.73%)

Closing price 04:00 PM Eastern

Extended Trading

$38.62 +0.01 (+0.01%)

As of 06:17 PM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Elanco Animal Health NYSE:ELAN

$13.94 +0.52 (+3.83%)

Closing price 03:59 PM Eastern

Extended Trading

$13.74 -0.20 (-1.43%)

As of 05:26 PM Eastern

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Tarsus Pharmaceuticals NASDAQ:TARS

$43.92 -0.16 (-0.36%)

Closing price 04:00 PM Eastern

Extended Trading

$43.96 +0.03 (+0.08%)

As of 04:20 PM Eastern

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Verona Pharma NASDAQ:VRNA

$84.34 -1.20 (-1.40%)

Closing price 04:00 PM Eastern

Extended Trading

$83.98 -0.36 (-0.43%)

As of 07:56 PM Eastern

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time